Craig-Hallum raised the firm’s price target on Eton Pharmaceuticals (ETON) to $28 from $26 and keeps a Buy rating on the shares following Q1 earnings, which was another strong performance. The company reiterated an $80M run-rate goal by year-end, though the firm sees this as conservative based on current trends and has modeled slightly above this level.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue